NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- 1 dead, 13 missing after midsize bus goes missing in north China
- Five dead in landslide in Southwest China
- Nation boosts global AI governance
- Former nuclear base keeps pioneering spirit alive
- China activates emergency response for flood control in Beijing
- China expands low-orbit internet network with new launch
